Why the study?
Echinochrome A can modulate cardiovascular disease via anti-inflammatory and antioxidant activity, but the underlying mechanism was unclear.
Does echinochrome A prevent endothelial-mesenchymal transition and improve myocardial dysfunction in ischemic cardiac injury models?
Does echinochrome A prevent endothelial-mesenchymal transition and improve myocardial dysfunction in ischemic cardiac injury models?
Answers are grounded in this paper and cite their sources.
Echinochrome A shows potential as a cardioprotective therapy by inhibiting endothelial-mesenchymal transition and reducing cardiac fibrosis after myocardial infarction.
Endothelial-mesenchymal transition (EndMT) is a process by which endothelial cells (ECs) transition into mesenchymal cells (e.g., myofibroblasts and smooth muscle cells) and induce fibrosis of cells/tissues, due to ischemic conditions in the heart. Previously, we reported that echinochrome A (EchA) derived from sea urchin shells can modulate cardiovascular disease by promoting anti-inflammatory and antioxidant activity; however, the mechanism underlying these effects was unclear. We investigated the role of EchA in the EndMT process by treating human umbilical vein ECs (HUVECs) with TGF-β2 and IL-1β, and confirmed the regulation of cell migration, inflammatory, oxidative responses and mitochondrial dysfunction. Moreover, we developed an EndMT-induced myocardial infarction (MI) model to investigate the effect of EchA in vivo. After EchA was administered once a day for a total of 3 days, the histological and functional improvement of the myocardium was investigated to confirm the control of the EndMT. We concluded that EchA negatively regulates early or inflammation-related EndMT and reduces the myofibroblast proportion and fibrosis area, meaning that it may be a potential therapy for cardiac regeneration or cardioprotection from scar formation and cardiac fibrosis due to tissue granulation. Our findings encourage the study of marine bioactive compounds for the discovery of new therapeutics for recovering ischemic cardiac injuries.
No takes yet. Share an insight, caveat, or question.
Song et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: